PulseGLP
PulseGLP Wiki

Compounded GLP-1 Advertising Risk Signals

A living reference for compounded semaglutide and tirzepatide advertising claims, disclosures, and observed ad-market language.

Last updated: 2026-05-26. This page is generated from the PulseGLP second brain and should be treated as market-intelligence context, not medical or legal advice.

Current Signal Snapshot

  • 3,073 matching patient-evidence rows in the last 180 days.
  • 913 matching Meta ad observations in the last 180 days.
  • 320 matching FDA warning-letter findings in the enforcement corpus.
  • Newest matching patient evidence was observed 5/22/2026.
  • Newest matching ad observation was seen 5/22/2026.

Patient Evidence Patterns

  • Top drug/entity mix in sampled evidence: Tirzepatide (17), Semaglutide (10), Wegovy (4), Mounjaro (2), Zepbound (2), Ozempic (1).
  • Highest-volume sampled sources: r/Tirzepatide (17), r/Semaglutide (10), r/WegovyWeightLoss (4), r/Zepbound (2), r/Mounjaro (1), r/Mounjaro UK (1).
  • Classification mix in sampled evidence: Analytical (15), Risk-Alert (10), Neutral-Low (7), Positive (4).
  • Use Ask Pulse to inspect source-level citations before turning this signal into campaign copy, clinical workflow changes, or compliance guidance.

FDA And Compliance Context

  • Most common matching warning-letter finding types: other-fda-cited-claim (11), product-sourcing-ambiguity (2), sameness-or-fda-approval-implication (2), unapproved-product-risk (2), unsupported-efficacy-or-safety-claim (1).
  • Recent companies/products represented in matching findings include Mile High Compounds LLC / Drugs; Belle Health LLC dba Belle / Drugs; Dripgym Mobile Parent, LLC dba Amp Health / Drugs.
  • PulseGLP tracks potential FDA-cited language patterns; it does not determine whether a claim is compliant or non-compliant.

Ad Market Signals

  • Advertisers appearing in the sampled matching set: Beyond the Scale (3), Zimmerman Reed (3), American Health Report (2), 40 Plus & Fabulous (1), Bailey Health Solutions (1), BeSlimMD Weight Loss (1).
  • Creative Intelligence can inspect the underlying ads for risk-level labels, themes, landing URLs, and repeated positioning patterns.
  • Ad counts reflect observed library rows and can include deduped or updated observations from recovered collection runs.

How Ask Pulse Uses This Page

  • Ask Pulse retrieves this page as durable context before it looks at fresh raw evidence.
  • The page helps keep answers consistent across repeated questions about the same topic.
  • Raw evidence citations are still required for specific factual claims or patient-language details.

Related PulseGLP Wiki Pages

4,306 matched sources Confidence 95/100 Updated 5/26/2026